News

VIAject is Biodel’s investigational ultra-rapid-acting injectable human insulin intended for meal-time use by people with type 1 and type 2 diabetes. The new drug application (NDA) will be

The sulfacetamide sodium topical suspension, 10% (lotion) has been determined to be therapeutically equivalent to Sanofi-Aventis’s Klaron lotion, 10%, which is indicated for the topical treatment of acne.

The Archexin Phase IIa trial is a single-arm, open-label study conducted at global sites in the US and India. Archexin will be administered in combination with gemcitabine in

Under the terms of the agreement, Aveo will receive an up-front payment and is eligible to receive milestone payments based upon the achievement of specified development goals. Biogen

Novartis has received a positive opinion supporting EU approval of Glivec as a post-surgery treatment for patients at significant risk of relapse following removal of gastrointestinal stromal tumors.

Ms Leonard said: “After having achieved my goal of successfully identifying and acquiring a FDA cleared, CLIA waived product that offers CLX the opportunity to become market leader

Mr Stout served most recently as president of pharmaceuticals at GlaxoSmithKline, where he was responsible for the company’s global pharmaceutical operations, from January 2003 to February 2008. Prior

Since 2001, Dr Werner has been a managing director and senior vice president of GlaxoSmithKline (GSK) and has served as CEO of the GSK Foundation until earlier this

Most recently, Mr DuFresne served as president and CEO of Pacgen Biopharmaceuticals. Prior to that, Mr DuFresne served as president and CEO of Zelos Therapeutics and ConjuChem and